Trial Profile

An Open Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt's Macular Degeneration

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 16 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SAR 422459 (Primary)
Indications Stargardt disease
Focus Adverse reactions
Sponsors Oxford BioMedica; Sanofi

Most Recent Events

01 Jun 2023 Planned End Date changed from 1 Aug 2034 to 29 Aug 2033.
01 Jun 2023 Planned primary completion date changed from 1 Aug 2034 to 29 Aug 2033.
10 Aug 2020 Planned End Date changed from 1 Aug 2033 to 1 Aug 2034.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com